Novocure Ltd (NVCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novocure Ltd (NVCR) has a cash flow conversion efficiency ratio of -0.041x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.52 Million) by net assets ($330.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NVCR market cap overview for the company's overall valuation and market capitalisation.
Novocure Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Novocure Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Novocure Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novocure Ltd ranked by their cash flow conversion efficiency. Explore Novocure Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Coty Inc
NYSE:COTY
|
-0.060x |
|
Shenzhen Airport Co Ltd
SHE:000089
|
0.035x |
|
China Automotive Engineering Research Institute Co Ltd
SHG:601965
|
0.016x |
|
CSSC Steel Structure Engineering Co Ltd
SHG:600072
|
-0.056x |
|
Gränges AB (publ)
ST:GRNG
|
-0.026x |
|
Guangdong Jia Yuan Technology Co Ltd
SHG:688388
|
0.006x |
|
Embracer Group AB (publ)
ST:EMBRAC-B
|
0.074x |
|
Leyard Optoelectronic
SHE:300296
|
0.020x |
Annual Cash Flow Conversion Efficiency for Novocure Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Novocure Ltd from 2013 to 2025. View current stock price of Novocure Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $340.47 Million | $-49.03 Million | -0.144x | -96.71% |
| 2024-12-31 | $360.18 Million | $-26.37 Million | -0.073x | +63.81% |
| 2023-12-31 | $362.50 Million | $-73.34 Million | -0.202x | -389.89% |
| 2022-12-31 | $441.17 Million | $30.79 Million | 0.070x | -65.38% |
| 2021-12-31 | $410.49 Million | $82.76 Million | 0.202x | -3.11% |
| 2020-12-31 | $476.53 Million | $99.15 Million | 0.208x | +70.23% |
| 2019-12-31 | $217.79 Million | $26.62 Million | 0.122x | +835.72% |
| 2018-12-31 | $112.26 Million | $-1.86 Million | -0.017x | +94.31% |
| 2017-12-31 | $113.56 Million | $-33.13 Million | -0.292x | +61.40% |
| 2016-12-31 | $142.34 Million | $-107.59 Million | -0.756x | -89.80% |
| 2015-12-31 | $250.82 Million | $-99.88 Million | -0.398x | +47.50% |
| 2014-12-31 | $97.88 Million | $-74.24 Million | -0.759x | -147.18% |
| 2013-12-31 | $171.78 Million | $-52.72 Million | -0.307x | -- |
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TT… Read more